FIELD: medicine.
SUBSTANCE: invention refers to medicine and concerns angiogenesis-preventing immunotherapy. Invention substance includes immunogenic compositions for treatment of disorders associated with angiogenesis intensification, containing oligonucleotides, coding polypeptides VEGFR2, introduced as a part of plasmid or viral vectors, as well as polypeptides VEGFR2, oligonucleotides, coding autologous VEGF with damaged function of receptor activation, polypeptides VEGF and their combinations. Immunogenic compositions can be used for treatment of malignant neoplasms and metastasises, at benign neoplasm and chronic inflammatory and autoimmune diseases. Advantage of invention lies in humoral and cellular immunity induction by means of specified compositions.
EFFECT: development of effective method angiogenesis preventive immunotherapy.
19 cl, 11 ex, 7 tbl
Title | Year | Author | Number |
---|---|---|---|
RECOMBINANT ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), OBTAINED BY VARIABLE REGION MUTAGENESIS | 2011 |
|
RU2557309C2 |
DNA VACCINE AGAINST PROLIFERATING ENDOTHELIAL CELLS AND USES THEREOF | 2003 |
|
RU2318019C2 |
DNA COMPOSITION FOR INDUCING IMMUNE RESPONSE ON TUMOUR-ASSOCIATED MACROPHAGUES | 2007 |
|
RU2459631C2 |
DNA-VACCINE AGAINST TUMORAL GROWTH AND WAYS OF THEIR APPLICATION | 2004 |
|
RU2343195C2 |
RECOMBINANT PROTEIN CARRYING HUMAN PAPILLOMA VIRUS EPITOPES, PROTEIN EMBEDDED ADENYLATECYCLASE OR ITS FRAGMENT, ITS THERAPEUTIC APPLICATION | 2005 |
|
RU2441022C2 |
VACCINE COMPOSITION POTENTIATED WITH DNA AND ANTIGEN COMBINATION | 2002 |
|
RU2294212C2 |
VEGF BINDING V9 NANOANTIBODY AND METHOD OF OBTAINING SAID ANTIBODY, V9-CODING NUCLEOTIDE SEQUENCE AND VECTOR CONTAINING SAID SEQUENCE, ENDOTHELIAL CELL PROLIFERATION INHIBITION METHOD | 2008 |
|
RU2395521C1 |
AGENTS AND METHODS BASED ON USING FIBRONECTIN OF DOMAIN EDA | 2006 |
|
RU2430738C2 |
COMBINATIONS OF GROWTH-REGULATING FACTORS AND HORMONES FOR NEOPLASIA TREATMENT | 2003 |
|
RU2321422C2 |
INTERLEUKINE-15 PEPTIDE ANTAGONIST | 2005 |
|
RU2396276C2 |
Authors
Dates
2008-07-27—Published
2003-04-11—Filed